BUSINESSSCMP CHINA
US biotech firm developing therapies for infant brain injuries plans Hong Kong listing
A US-based biotech firm, Axiom Biosciences, plans to pursue a primary Hong Kong IPO in 2027 to raise at least US$200 million for its AI-driven therapies targeting infant brain injuries, with a secondary US listing planned for 2029. The company is part of a growing trend of AI-powered medical firms seeking capital in Hong Kong.
Mentioned
Related Signal
Adjacent reporting
- US biotech firm developing therapies for infant brain injuries plans Hong Kong listing
- US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom
- STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
- Hong Kong-Listed Biotech Insilico Is Said to Explore UAE Listing
- Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals